BillionToOne Is Solving One of Biotech’s Hardest Problems

Predictions and Expectations:

• David and Oguzhan expect that in about 20% of patients undergoing curative-intense surgery for stage one or two cancers, microscopic residue will remain undetected by scans, and they believe their technology can detect this remnant tumor DNA.
• The speakers predict that if the company achieves the ability to detect microscopic DNA levels, the same technical challenge will apply to detecting those signals in healthy patients, representing the "eventual goal" of cancer screening.
• Oguzhan states they expect that once the company reaches the stage of detecting early-stage cancer before it spreads, the ability to remove tumors early will make "a dent in cancer that really has happened in the last 100 years."
• The narrator notes that if the founders had attempted to solve early detection from the start without a step-by-step approach, they would have needed to raise "more than a billion dollars" without generating revenue, implying a belief that the current path was necessary for success.

Timelines and Milestones:

• The company expected to be "maybe less than a year away" from launching an ultra-sensitive MRD test for stage one to cancer patients at the time of the interview.
• Oguzhan states that as early as 2018, the company laid out a three-step plan: start with prenatal genetics, move to late-stage cancers, and then move to early-stage cancers.
• The team launched an early version of their cancer test commercially in 2023, marking the completion of the second step in their roadmap.
• The company plans to expand its current facility to process "close to 2 million tests per year," which they estimate would cover "every one in three babies" tested with their test.
• Oguzhan describes a future goal where the company can "screen everyone once a year" to conclusively identify small groups with early-stage cancer.
• The narrator mentions that the company built a state-of-the-art lab in 2022.

Technology and Product Direction:

• The speakers plan to use the same core technology currently used for prenatal testing and late-stage cancer detection to solve the problem of detecting microscopic residual disease in stage one and two cancer patients.
• The company is working toward using their technology for early-stage detection to catch cancer "before it ever reaches stage one."
• Oguzhan believes that expanding into cancer screening (step four) is technically feasible once the company masters detecting microscopic remnant tumor DNA.
• The team intends to continue using an interdisciplinary hiring model where individual scientists lead small teams owning end-to-end product development, with reports going directly to David and Oguzhan.
• The company has already incorporated AI and computer vision into their "Accessioning in 60 Seconds" project to handle sample identity preservation and process acceleration.

Market and Industry Outlook:

• The narrator reports that one in 11 babies born in America this year will be screened by a genetic test that didn't exist a decade ago.
• The company aims to create diagnostics that "would someday be universally adopted" for prenatal genetic testing, replacing invasive procedures like amniocentesis used only in high-risk pregnancies.
• Oguzhan hopes to help "millions of patients" by addressing the most common genetic disorders in the world, such as sickle-cell and beta-thalassemia.
• The speakers observe that a physician who was the sole user two months after launch is now "starting to actually send us blood tests from pretty much all of his cancer patients," indicating early market adoption trends.

Company Plans:

• Oguzhan states they expect to expand into close to 2 million tests per year using their current facility.
• The founders plan to grow by taking resources from successful commercial products to launch more expensive and difficult products in larger markets.
• The company intends to maintain a structure of "many startups within the larger company" where small R&D teams own entire products to accelerate iteration.
• Oguzhan notes that even after going public, the employees are not retiring, indicating a continued focus on growth and challenge rather than exit.

Financial Guidance:

• No forward-looking financial guidance or specific revenue targets were stated in the transcript.

Risks and Caveats:

• The speakers warn that changing healthcare while growing fast and remaining profitable is "even more difficult" than just changing healthcare.
• Oguzhan acknowledges that joining the company is "probably going to be one of the most difficult things that you are ever going to do."
• The founders fear that attempting to solve early detection from the very beginning without the step-by-step approach would have been impossible due to the capital requirements ("more than a billion dollars") and lack of initial revenue.
• Oguzhan admits that they might be "very proud" of what they achieve even if they "just solve the biggest prenatal problems," implying a contingency if the cancer goals are not met.
• The company warns that the scarcity of interdisciplinary talent capable of bridging data science and chemistry was a historical barrier that no one else had successfully overcome before.

Confidence and Disagreement:

• The speakers express high confidence in their unique approach, stating they believe they can convert a difficult biology problem into a "simple mathematical problem" using synthetic DNA to remove amplification noise.
• Oguzhan believes the company's ability to achieve initial commercialization in prenatal genetics provided the necessary resources to build new tests and improve existing ones.
• The founders state that the same technology can be applied to both fetal and tumor DNA because "fundamentally there is nothing different" between cell-free fetal DNA and cell-free tumor DNA.
• Oguzhan remains confident that their step-by-step approach allowed them to solve a problem that others have been chasing as a "holy grail" without having the resources to do so immediately.